ABOUT

OUR COMPANY

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1/2a investigator-initiated study targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.

Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.

Mission Statement

We are committed to delivering novel solutions to cancer patients in need. We seek to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Management Team

Onconova Therapeutics is led by a management team with significant expertise in targeted cancer therapeutics, clinical development, and commercialization

Steven M. Fruchtman, M.D.
President & CEO

Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer. He was promoted to President in July 2018 and to President & CEO in January 2019. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals.

Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and serves as an external reviewer for multiple medical journals.

Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.

Mark Guerin
Chief Operating Officer and CFO

Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013. He was promoted to Chief Operating Officer and CFO in June 2022. Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly-acquired private equity portfolio companies.

Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, and CFM professional certifications.

Mark S. Gelder, M.D.
Chief Medical Officer

Dr. Gelder joined Onconova Therapeutics in June of 2021 as Chief Medical Officer (CMO). He has more than 35 years of experience in clinical development, medical affairs, and medical marketing and expertise that specifically covers the development of kinase inhibitors as cancer therapeutics. He was most recently the CMO of Elevar Therapeutics, where he led the company’s clinical development, medical affairs, regulatory affairs, and preclinical teams. Prior to his time at Elevar, Dr. Gelder served as the CMO of Pierian Biosciences (formerly DiaTech Oncology), Accelovance, Inc., and Heron Therapeutics, Inc.

Dr. Gelder also has extensive experience at large pharmaceutical companies, as he previously worked in global medical affairs and led therapeutic oncology programs for Pfizer, Wyeth, and Bayer. Dr. Gelder has led successful early- and late-stage global clinical trials and has been involved in the approval and launch of several cancer therapeutics. Prior to his career in the biopharmaceutical industry, Dr. Gelder was an investigator in multiple clinical trials and authored numerous scientific papers in the areas of women’s health and oncology. He earned his M.D. from the University of Virginia School of Medicine and completed a fellowship in gynecologic oncology. He is a Fellow of the American College of Physicians and the American College of Obstetrics and Gynecology.

In his role as Onconova’s CMO, Dr. Gelder leads ON 123300’s clinical development, facilitates the progression of rigosertib’s investigator-initiated trials, and evaluates potential product candidates for in-licensing.

Adar Makovski Silverstein, Ph.D.
Senior Director and Head of Corporate Development

Dr. Makovski Silverstein joined Onconova in December 2021 as Director, Corporate Development, and was promoted to Senior Director and Head of Corporate Development in June 2022. Previously, Dr. Makovski-Silverstein worked at Amgen as Sr. Licensing Associate, Business Development, External R&D. She was responsible for evaluating external scientific opportunities across all therapeutic areas and managing processes within business development and cross functional teams. Prior to her time at Amgen, Dr. Makovski Silverstein interned as a member of the Research Program Management Team at Regeneron. She also worked as a marketing analyst graduate student consultant at Roche Sequencing Solutions. Dr. Makovski Silverstein earned her Ph.D. in Biotechnology from Bar-Ilan University in Israel and completed a post-doctoral fellowship at the City of Hope in Duarte, California.

Matthew Parris
Vice President, Clinical Operations

Mr. Parris joined Onconova Therapeutics in August 2018 as Senior Director, Clinical Operations, and is responsible for overseeing and managing the Clinical Operations team and the cross functional project teams. He was promoted to Vice President, Clinical Operations in January 2021.

Mr. Parris has clinical development experience in multiple therapeutic areas, with a focus on Oncology and Hematology indications across a wide variety of therapeutic agents. He has over 24 years of industry experience, initially in Europe and since 2003 in the United States, holding management positions in contract research organizations as well as small pharma companies.

Previously, Mr. Parris served as Director of Clinical Operations for Inovio Pharmaceuticals, Vice President of Clinical Development for Eleison Pharmaceuticals, and Director of Clinical Operations at Aegerion Pharmaceuticals. He has a Bachelor of Science Degree, with honors, from Imperial College in London.

Stephen Cosenza, Ph.D.
Lead Scientist and Study Monitor

Dr. Stephen Cosenza joined Onconova Therapeutics in January 2021 as Lead Scientist and Study Monitor. He is presently involved in the development of all compounds in Onconova’s pipeline, participates in business development activities, and assists with clinical operations. He has been a preclinical drug development consultant for Onconova since its inception in 1998. He has 36 years of experience in molecular biology, specializing in the regulation of the normal mammalian cell cycle and the initiation and progression of cancer cell growth. He has participated in preclinical and IND-enabling work for all of Onconova’s compounds that have been approved for clinical trials. Dr. Cosenza has extensive experience in cell culture and working with the in vitro and in vivo animal models required for the study and development of small molecular weight compounds as cancer therapeutics.

Previously, Dr. Cosenza worked at the Icahn School of Medicine at Mt. Sinai in the Department of Oncological Sciences and The Fels Institute for Cancer Research and Molecular Biology as Senior Researcher under the mentorship of Dr. E. Premkumar Reddy, one of Onconova’s founders. Dr. Cosenza has served as an external reviewer for various scientific journals and is an author of over 45 peer-reviewed articles.

Dr. Cosenza received his doctorate degree in the department of Microbiology and Immunology at Temple University School of Medicine. He performed his postdoctoral fellowship at the Wistar Institute and The Fels Institute for Cancer Research and Molecular Biology.

Board of Directors

A group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.

James J. Marino, J.D.
Chairman

Mr. Marino brings more than three decades of experience advising numerous leading life science companies in connection with corporate transactions and strategic alliances. He has served as a Director of Onconova since July 2015, a Director of Celldex Therapeutics, Inc. since March 2017, and previously as a Director of Pharmacopeia, Inc. Mr. Marino served on the Board of Trustees of Wake Forest University and its renowned Medical Center, and previously served on the Board of Trustees of Robert Wood Johnson University Hospital. He is a co-founder of BioNJ, a trade association of biotechnology companies. Mr. Marino was a partner with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office, and focused on the representation of leading life sciences companies in a broad range of corporate transactions including innovative strategic alliances, joint-ventures, and spin-offs. Mr. Marino received his BA, JD, and MBA from Rutgers University.

Steven M. Fruchtman, M.D.
President & CEO

Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.

Peter Atadja, Ph.D.

Peter Atadja, Ph.D., joins Onconova’s Board with over two decades of experience in the pharmaceutical industry. He is currently the Chief Scientific Officer (CSO) of CommBio Therapeutics, a biotechnology company dedicated to developing a new class of medicine for a spectrum of diseases by modulating intestinal functions. Prior to joining CommBio, Dr. Atadja co-founded and served as the CSO of K36 therapeutics, a biotechnology company that aims to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics. From 1997 – 2021, Dr. Atadja held roles of increasing responsibility at Novartis Pharmaceuticals, most recently serving as the company’s Executive Director & Head, Drug Discovery & Translational Research. While at Novartis, he led the discovery, development, and registration of the first FDA and EMA approved HDAC inhibitor (FARYDAK®) and launched three major research programs (oncology, liver diseases, regenerative medicine), resulting in the addition of 20 novel targets, eight first-in-class candidates, and two clinical candidates to the company’s global pipeline. In 2008, Dr. Atadja was the recipient of Novartis’ highest award in drug discovery, the VIVA Award. He has a Ph.D. in molecular oncology from University of Calgary, a Master of Science in pharmaceutical and medicinal chemistry from Hebrew University, and a Bachelor of Pharmacy in medicinal chemistry from Kumasi University of Science and Technology, in Kumasi, Ghana.

Trafford Clarke, Ph.D.

Trafford Clarke, Ph.D., is a pharmaceutical industry veteran who has dedicated his career to the discovery, development, and launch of new medicines. He spent 31 years working in roles of increasing responsibility at Eli Lilly and Company, most recently serving as a Managing Director and UK Research and Development Site Head. In this role, Dr. Clarke led a team of approximately 700 people and oversaw significant improvements in site productivity, infrastructure investment, and ethics and compliance standards. As Eli Lilly’s European Federation of Pharmaceutical Industries and Associations R&D representative, Dr. Clarke was a member of the Research Directors Group and championed Lilly’s strategic engagement and leadership of 32 European Union Innovative Medicine Initiative projects. He has previously served as Board Member for Eli Lilly and Company Ltd. UK and on the Innovation Board of the Association of the British Pharmaceutical Industry. Dr. Clarke has a Ph.D. in organic chemistry from Imperial College, London and a Bachelor of Science in organic chemistry from University of Liverpool.

Jerome Groopman, M.D.

Dr. Groopman holds the Dina and Raphael Recanati Chair of Medicine at the Harvard Medical School and is Chief of Experimental Medicine at the Beth Israel Deaconess Medical Center. He received his B.A. from Columbia College summa cum laude and his M.D. from Columbia College of Physicians and Surgeons in New York where he was elected to AOA. He served his internship and residency in internal medicine at the Massachusetts General Hospital, then his specialty fellowships in hematology and oncology at the University of California and Harvard Medical School. Dr. Groopman chaired the Advisory Committee to the FDA for Biological Response Modifiers. He serves on several scientific editorial boards and has published many research papers. He was elected to the Institute of Medicine of the National Academy of Sciences in 2000. Dr. Groopman’s research has focused on blood development, cancer, and AIDS, and he has been a major participant in the development of many AIDS-related therapies. He is a staff writer for The New Yorker and has written for The New York Times and The Washington Post. He is author of “The Measure of Our Days” (1997), “Second Opinions” (2000), “The Anatomy of Hope” (2004), and the recently released, “How Doctors Think.” “The Measure of Our Days,” explores the spiritual lives of patients with serious illness and was the basis for the ABC Television series “Gideon’s Crossing.

Viren Mehta, Pharm.D.

Dr. Mehta, Managing Member of Mehta Partners, has over thirty years of experience in the pharmaceutical and biotechnology industry, investment research, strategic advisory services, and asset management. Prior to founding Mehta and Isaly, where he pioneered an in-depth valuation methodology for biotechnology companies, Dr. Mehta was a part of the strategic planning team of the International Division at Merck & Co. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an M.B.A. Degree from the Anderson School of Business at the University of California, Los Angeles.

M. Teresa Shoemaker

Ms. M. Teresa Shoemaker served as the President and CEO of commercial-stage specialty pharmaceutical company Medexus Pharma, Inc. from October 2018 to May of 2020. She has extensive experience in senior leadership roles with a broad range of commercial and operational expertise in the life science industry, including her role as National Sales Director and later as Senior Director of U.S. Commercial Operations for Pharmion Corporation, where she was integral in the launch of azacitidine for myelodysplastic syndromes. In 2008, when Celgene Corporation acquired Pharmion, Ms. Shoemaker remained as Executive Director of Strategic Commercial Operations working as part of the executive transition team.

Ms. Shoemaker joined Onconova’s Board of Directors in May of 2020 and brings more than 30 years of extensive commercial and leadership experience to the Company.

Jack E. Stover

Since December 2015, Mr. Stover has served as Interim President and CEO of Interpace Diagnostics Group, Inc., formerly known as “PDI, Inc.”, and has served on their board of directors since August 2005. He was the chair of PDI’s audit committee from August 2005 until December 2015. Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (“Zebec”) since April 2014. Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc. (“Gynetics”), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.

Scientific Advisory Board

Onconova Therapeutics is advised by a group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.

Alan R. Williamson, Ph.D.
Chairman

Dr. Williamson has extensive experience in pharmaceutical discovery. He served as Vice President of Basic Research and Vice President, Research Strategy Worldwide, for Merck. Previously he was with Glaxo, UCLA, University of Glasgow, and the National Institute for Medical Research, U.K. He is the recipient of the Colworth Medal of the Biochemical Society and a member of the EMBL. He was elected Fellow of the Royal Society of Edinburgh in 1976 and Fellow of the Institute of Biology in 1982. Dr. Williamson sits on the scientific advisory board of Illumina. He is a consultant to the venture capital firm Abingworth Management Ltd.

David R. Parkinson, M.D.
Venture Partner at NEA

Dr. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 to 2012, Dr. Parkinson served as President and CEO of Nodality Inc., a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making. Previously, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. At Biogen he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec^®, Femara^®, Zometa^®, Kepivance^®, and Vectibix^®. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. He received his M.D. as gold medalist from the University Of Toronto Faculty Of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past President of the International Society of Biological Therapy, and past Editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA’s Science Board. He was recently elected to the Board of Directors of the American Association of Cancer Research, and he continues to serve as Chairman of the AACR Finance Committee.

George F. Vande Woude, Ph.D.
Van Andel Research Institute

Dr. Vande Woude served as research virologist for the US Department of Agriculture at Plum Island Animal Disease Center prior to his career at the National Cancer Institute (NCI) where he served successively as Head of the Human Tumor Studies and Virus Tumor Biochemistry Sections, Chief of the Laboratory of Molecular Oncology, and Director of the Advanced Bioscience Laboratories-Basic Research Program. He was Special Advisor to the Director of NCI and served to reorganize the intramural basic science at NCI. In 1999, he was selected to be the first Director of the newly created Van Andel Research Institute in Grand Rapids, Michigan. Dr. Vande Woude is the recipient of many awards honoring his contributions, is author of over 250 scientific research articles and over 60 articles in books or monographs, and is a member of the National Academy of Sciences.

Ross C. Donehower, M.D.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Dr. Donehower is Professor of Oncology, the Director of Medical Oncology/Hematology Fellowship Training program and a Director in the Division of Medical Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His current clinical interests lie in gastrointestinal cancers and drug development. Dr. Donehower performed his postgraduate training in internal medicine at Johns Hopkins, and has worked at the U.S. Public Health Service and at the National Cancer Institute in Bethesda. He is currently director of both the Division of Medical Oncology in the Department of Oncology and of the Medical Oncology Fellowship Training Program at the Johns Hopkins Kimmel Comprehensive Cancer Center as well as a Professor of Oncology and Medicine. Dr. Donehower performed pioneering work in clinical studies of paclitaxel (Taxol^®), one of the most important chemotherapy agents developed in the last several decades.

Stephen Nimer, M.D.
Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics

Dr. Nimer is a Professor of Medicine, Biochemistry & Molecular Biology and Director at the Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics. He received his medical degree from the University of Chicago Pritzker School of Medicine and completed his Internship and Residency in Internal Medicine at the University of California-Los Angeles (UCLA) School of Medicine, where he was named Chief Medical Resident. He remained at UCLA for his Fellowship in Hematology and Oncology. Dr. Nimer is a Fellow of the American College of Physicians and a member of the American Society for Clinical Investigation, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is on the editorial boards of several journals, such as Leukemia Research and the American Journal of Oncology Review. He is a reviewer for the New England Journal of Medicine, Blood, and Nature Medicine. Dr. Nimer has published over 120 research articles and given numerous presentations at scientific meetings.

Anna Marie Skalka, Ph.D.
Fox Chase Cancer Center

Dr. Skalka is Professor, W.W. Smith Chair in Cancer Research and Senior Advisor to the President at the Fox Chase Cancer Center in Philadelphia. She is a leading expert in the molecular biology of retroviruses and the molecular basis of cancer. In recognition of her outstanding accomplishments, Dr. Skalka has been elected as a Fellow to the American Academy of Microbiology, the American Association for the Advancement of Science, the American Academy of Arts and Science, and the New York Academy of Science.

ABOUT

About Onconova Therapeutics

Mission Statement

Management Team

Board of Directors

Scientific Advisory Board

Onconova Therapeutics

GET IN TOUCH

ABOUT ONCONOVA